臨床泌尿器科74巻10号

2020年09月発行

特集 令和最新版! 泌尿器がん薬物療法―手元に置きたい心強い一冊

〈各論〉

進行期胚細胞腫瘍の薬物療法

著者： 河野勤¹

所属機関： ¹佐々木研究所附属杏雲堂病院腫瘍内科

ページ範囲：P.770 - P.784

文献概要

▶ポイント

・BEP療法のなかのブレオマイシンは3剤のなかでの役割は一番小さい一方，その位置づけは非常に重要である．

・BEP療法は3週サイクルで行うことがきわめて重要である．

・救援化学療法においては，プラチナ不応性（platinum-refractory）などの予後因子を考慮して，治療方針を選択する（標準量化学療法あるいは大量化学療法）．

参考文献

1） Takizawa A, et al : Significance of thcg Assay in the Management of Testicular Cancer -- The Possibility of a Standard Assay in Testicular Cancer as an Alternative to FbetahCG Assay . Nihon Hinyokika Gakkai Zasshi 98 : 23-29, 2007

2） International Germ Cell Consensus Classification : A Prognostic Factor-Based Staging System for Metastatic Germ Cell Cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15 : 594-603, 1997

3） Williams SD, et al : Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and Either Vinblastine or Etoposide. N Engl J Med 316 : 1435-1440, 1987

4） Albers P, et al : Guidelines on Testicular Cancer : 2015 Update. Eur Urol 68 : 1054-1068, 2015

5） Kesler KA, et al : Outcomes Following Surgery for Primary Mediastinal Nonseminomatous Germ Cell Tumors in the Cisplatin Era. J Thorac Cardiovasc Surg, 2020 ［Online ahead of print］

6） Bower M, et al : Serum Tumor Markes and Their Role in Monitoring Germ Cell Cancers of the Testis. In : Vogelzang NJ, et al （eds） : Comprehensive Textbook of Genitouninary Oncology, Second Edition. Lippincott Williams & Wilkins, 2000

7） Hanna N, et al : Testicular Cancer : A Reflection on 50 Years of Discovery. J Clin Oncol 32 : 3085-3092, 2014

8） Loehrer PJ, Sr, et al : Importance of Bleomycin in Favorable-Prognosis Disseminated Germ Cell Tumors : An Eastern Cooperative Oncology Group Trial. J Clin Oncol 13 : 470-476, 1995

9） de Wit R, et al : Importance of Bleomycin in Combination Chemotherapy for Good-Prognosis Testicular Nonseminoma : A Randomized Study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15 : 1837-1843, 1997

10） Culine S, et al : Refining the Optimal Chemotherapy Regimen for Good-Risk Metastatic Nonseminomatous Germ-Cell Tumors : A Randomized Trial of the Genito-Urinary Group of the French Federation of Cancer Centers （GETUG T93BP）. Ann Oncol 18 : 917-924, 2007

11） Hinton S, et al : Cisplatin, Etoposide and Either Bleomycin or Ifosfamide in the Treatment of Disseminated Germ Cell Tumors : Final Analysis of an Intergroup Trial. Cancer 97 : 1869-1875, 2003

12） Samson MK, et al : Dose-Response and Dose-Survival Advantage for High Versus Low-Dose Cisplatin Combined with Vinblastine and Bleomycin in Disseminated Testicular Cancer. A Southwest Oncology Group Study. Cancer 53 : 1029-1035, 1984

13） Toner GC, et al : Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ-Cell Tumours : A Randomised Trial. Australian and New Zealand Germ Cell Trial Group. Lancet 357 : 739-745, 2001

14） Collette L, et al : Impact of the Treating Institution on Survival of Patients with “Poor-Prognosis” Metastatic Nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 91 : 839-846, 1999

15） Motzer RJ, et al : The Effect of a 7-Day Delay in Chemotherapy Cycles on Complete Response and Event-Free Survival in Good-Risk Disseminated Germ Cell Tumor Patients. Cancer 66 : 857-861, 1990

16） Feldman DR : State-of-the-Art Management of Germ Cell Tumors. Am Soc Clin Oncol Educ Book : 319-323, 2018

17） Fosså SD, et al : Filgrastim During Combination Chemotherapy of Patients with Poor-Prognosis Metastatic Germ Cell Malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 16 : 716-724, 1998

18） Culine S, et al : Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin with Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients with Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors : Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 26 : 421-427, 2008

19） Aapro MS, et al : 2010 Update of EORTC Guidelines for the Use of Granulocyte-Colony Stimulating Factor to Reduce the Incidence of Chemotherapy-Induced Febrile Neutropenia in Adult Patients with Lymphoproliferative Disorders and Solid Tumours. Eur J Cancer 47 : 8-32, 2011

20） Saxman SB, et al : Pulmonary Toxicity in Patients with Advanced-Stage Germ Cell Tumors Receiving Bleomycin with and without Granulocyte Colony Stimulating Factor. Chest 111 : 657-660, 1997

21） Kwan EM, et al : Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors. Clin Genitourin Cancer, 2017 ［Online ahead of print］

22） Fizazi K : Early Predicted Time to Normalization of Tumor Markers Predicts Outcome in Poor-Prognosis Nonseminomatous Germ Cell Tumors. J Clin Oncol 22 : 3868-3876, 2004

23） Motzer RJ, et al : Phase III Randomized Trial of Conventional-Dose Chemotherapy with or without High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Rescue as First-Line Treatment for Patients with Poor-Prognosis Metastatic Germ Cell Tumors. J Clin Oncol 25 : 247-256, 2007

24） Fizazi K, et al : Personalised Chemotherapy Based on Tumour Marker Decline in Poor Prognosis Germ-Cell Tumours （GETUG 13） : A Phase 3, Multicentre, Randomised Trial. The Lancet Oncology 15 : 1442-1450, 2014

25） Rejlekova K, et al : Severe Complications in Testicular Germ Cell Tumors : The Choriocarcinoma Syndrome. Front Endocrinol （Lausanne） 10 : 218, 2019

26） Massard C, et al : Poor Prognosis Nonseminomatous Germ-Cell Tumours （NSGCTs）: Should Chemotherapy Doses Be Reduced at First Cycle to Prevent Acute Respiratory Distress Syndrome in Patients with Multiple Lung Metastases? Ann Oncol 21 : 1585-1588, 2010

27） Gillessen S, et al : Low-Dose Induction Chemotherapy with Baby-BOP in Patients with Metastatic Germ-Cell Tumours Does Not Compromise Outcome : A Single-Centre Experience. Ann Oncol 21 : 1589-1593, 2010

28） Tryakin A, et al : Dose-Reduced First Cycle of Chemotherapy for Prevention of Life-Threatening Acute Complications in Nonseminomatous Germ Cell Tumor Patients with Ultra High Tumor Markers and/or Poor Performance Status. J Cancer Res Clin Oncol 144 : 1817-1823, 2018

29） Cafferty FH, et al : Long-Term Outcomes with Intensive Induction Chemotherapy （Carboplatin, Bleomycin, Vincristine and Cisplatin/Bleomycin, Etoposide and Cisplatin） and Standard Bleomycin, Etoposide and Cisplatin in Poor Prognosis Germ Cell Tumours : A randomised Phase II Trial （ISRCTN53643604）. Eur J Cancer 127 : 139-149, 2020

30） Kawai K, et al : Paclitaxel, Ifosfamide and Cisplatin Regimen Is Feasible for Japanese Patients with Advanced Germ Cell Cancer. Jpn J Clin Oncol 33 : 127-131, 2003

31） Kurobe M, et al : Paclitaxel, Ifosfamide, and Cisplatin （TIP） as Salvage and Consolidation Chemotherapy for Advanced Germ Cell Tumor. J Cancer Res Clin Oncol 141 : 127-133, 2014

32） Nonomura N, et al : Paclitaxel, Ifosfamide, and Nedaplatin （TIN） Salvage Chemotherapy for Patients with Advanced Germ Cell Tumors. Int J Urol 14 : 527-531, 2007

33） Uchida M, et al : Salvage Chemotherapy with Gemcitabine Plus Oxaliplatin for Patients with Testicular Germ Cell Cancer. Int J Clin Oncol 19 : 1112-1117, 2014

34） Miki T, et al : Irinotecan Plus Cisplatin Has Substantial Antitumor Effect as Salvage Chemotherapy Against Germ Cell Tumors. Cancer 95 : 1879-1885, 2002

35） Kojima T, et al : Identification of a Subgroup with Worse Prognosis Among Patients with Poor-Risk Testicular Germ Cell Tumor. Int J Urol 22 : 923-927, 2015

36） Adra N, et al : Prognostic Factors In Patients with Poor-Risk Germ-Cell Tumors : A Retrospective Analysis of the Indiana University Experience from 1990 to 2014. Ann Oncol 27 : 875-879, 2016

37） Zon RT, et al : Management Strategies and Outcomes of Germ Cell Tumor Patients with Very High Human Chorionic Gonadotropin Levels. J Clin Oncol 16 : 1294-1297, 1998

38） Nichols CR, et al : Dose-Intensive Chemotherapy in Refractory Germ Cell Cancer―A Phase I/II Trial of High-Dose Carboplatin And Etoposide with Autologous Bone Marrow Transplantation. J Clin Oncol 7 : 932-939, 1989

39） Einhorn LH : Salvage Therapy in Patients with Germ Cell Tumors. Am Soc Clin Oncol Educ Book 35 : e259-361, 2015

40） Loehrer PJ, et al : VP-16 Plus Ifosfamide Plus Cisplatin as Salvage Therapy in Refractory Germ Cell Cancer. J Clin Oncol 4 : 528-536, 1986

41） Loehrer PJ, Sr, et al : Salvage Therapy in Recurrent Germ Cell Cancer : Ifosfamide and Cisplatin Plus Either Vinblastine or Etoposide. Ann Intern Med 109 : 540-546, 1988

42） Ghosn M, et al : Salvage Chemotherapy in Refractory Germ Cell Tumors with Etoposide （VP-16） Plus Ifosfamide Plus High-Dose Cisplatin. A VIhP Regimen. Cancer 62 : 24-27, 1988

43） Motzer RJ, et al : The Role of Ifosfamide Plus Cisplatin-Based Chemotherapy as Salvage Therapy for Patients with Refractory Germ Cell Tumors. Cancer 66 : 2476-2481, 1990

44） Harstrick A, et al : Cisplatin, Etoposide, and Ifosfamide Salvage Therapy for Refractory or Relapsing Germ Cell Carcinoma. J Clin Oncol 9 : 1549-1555, 1991

45） Pizzocaro G, et al : Modified Cisplatin, Etoposide （or Vinblastine） and Ifosfamide Salvage Therapy for Male Germ-Cell Tumors. Long-term results. Ann Oncol 3 : 211-216, 1992

46） Farhat F, et al : Cisplatin and Ifosfamide with Either Vinblastine or Etoposide as Salvage Therapy for Refractory or Relapsing Germ Cell Tumor Patients : The Institut Gustave Roussy Experience. Cancer 77 : 1193-1197, 1996

47） McCaffrey JA, et al : Ifosfamide- and Cisplatin-Containing Chemotherapy as First-Line Salvage Therapy in Germ Cell Tumors : Response and Survival. J Clin Oncol 15 : 2559-2563, 1997

48） Loehrer PJ, Sr, et al : Vinblastine Plus Ifosfamide Plus Cisplatin as Initial Salvage Therapy in Recurrent Germ Cell Tumor. J Clin Oncol 16 : 2500-2504, 1998

49） ANecchi A, et al : Modified Cisplatin, Etoposide, and Ifosfamide （PEI） Salvage Therapy for Male Germ Cell Tumors : Long-Term Efficacy and Safety Outcomes. Ann Oncol 24 : 2887-2892, 2013

50） Kondagunta GV, et al : Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients with Relapsed Testicular Germ Cell Tumors. J Clin Oncol 23 : 6549-6555, 2005

51） Motzer RJ, et al : Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients with Relapsed Testicular Germ Cell Cancer. J Clin Oncol 18 : 2413-2418, 2000

52） Mead GM, et al : A Phase II Trial of TIP （Paclitaxel, Ifosfamide and Cisplatin） Given as Second-Line （Post-BEP） Salvage Chemotherapy for Patients with Metastatic Germ Cell Cancer : A Medical Research Council Trial. Br J Cancer 93 : 178-184, 2005

53） Mardiak J, et al : Paclitaxel Plus Ifosfamide and Cisplatin in Second-Line Treatment of Germ Cell Tumors : A Phase II Study. Neoplasma 52 : 497-501, 2005

54） Fujiwara M, et al : Cisplatin, Gemcitabine, and Paclitaxel as a Salvage Second-Line Therapy for Metastatic Germ-Cell Cancer. Clin Genitourin Cancer, 2020 ［Online ahead of print］

55） Beyer J, et al : High-Dose Chemotherapy as Salvage Treatment in Germ Cell Tumors : A Multivariate Analysis of Prognostic Variables. J Clin Oncol 14 : 2638-2645, 1996

56） Lorch A, et al : Prognostic Factors in Patients with Metastatic Germ Cell Tumors Who Experienced Treatment Failure with Cisplatin-Based First-Line Chemotherapy. J Clin Oncol 28 : 4906-4911, 2010

57） Simonelli M, et al : Intensified Chemotherapy with Stem-Cell Rescue in Germ-Cell Tumors. Ann Oncol 23 : 815-822, 2012

58） Lorch A, et al : Conventional-Dose Versus High-Dose Chemotherapy as First Salvage Treatment in Male Patients with Metastatic Germ Cell Tumors : Evidence from a Large International Database. J Clin Oncol 29 : 2178-2184, 2011

59） Einhorn LH, et al : High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors. N Engl J Med 357 : 340-348, 2007

60） Adra N, et al : High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors : The Indiana University Experience. J Clin Oncol 35 : 1096-1102, 2017

61） Lorch A, et al : Sequential Versus Single High-Dose Chemotherapy in Patients with Relapsed or Refractory Germ Cell Tumors : Long-Term Results of a Prospective Randomized Trial. J Clin Oncol 30 : 800-805, 2012

62） Feldman DR, et al : TI-CE High-Dose Chemotherapy for Patients with Previously Treated Germ Cell Tumors : Results and Prognostic Factor Analysis. J Clin Oncol 28 : 1706-1713, 2010

63） Selle F, et al : A Phase II Trial of High-Dose Chemotherapy （HDCT） Supported by Hematopoietic Stem-Cell Transplantation （HSCT） in Germ-Cell Tumors （GCTs） Patients Failing Cisplatin-based Chemotherapy : The MulticentricTAXIF II Study. Ann Oncol 25 : 1775-1782, 2014

64） Nieto Y, et al : Bevacizumab/High-Dose Chemotherapy with Autologous Stem-Cell Transplant for Poor-Risk Relapsed or Refractory Germ-Cell Tumors. Ann Oncol 26 : 2125-2132, 2015

65） Hinton S, et al : Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors （E9897） : A Trial of the Eastern Cooperative Oncology Group. J Clin Oncol 20 : 1859-1863, 2002

66） Kollmannsberger C, et al : Combination Chemotherapy with Gemcitabine Plus Oxaliplatin in Patients with Intensively Pretreated or Refractory Germ Cell Cancer : A Study of the German Testicular Cancer Study Group. J Clin Oncol 22 : 108-114, 2004

67） Pectasides D, et al : Gemcitabine and Oxaliplatin （GEMOX） in Patients with Cisplatin-Refractory Germ Cell Tumors : A Phase II Study. Ann Oncol 15 : 493-497, 2004

68） De Giorgi U, et al : Phase II Study of Oxaliplatin and Gemcitabine Salvage Chemotherapy in Patients with Cisplatin-Refractory Nonseminomatous Germ Cell Tumor. Eur Urol 50 : 1032-1039, 2006

69） Bokemeyer C, et al : Combination Chemotherapy with Gemcitabine, Oxaliplatin, and Paclitaxel in Patients with Cisplatin-Refractory or Multiply Relapsed Germ-Cell Tumors : A Study of the German Testicular Cancer Study Group. Ann Oncol 19 : 448-453, 2008

70） Oechsle K, et al : Long-Term Survival After Treatment with Gemcitabine and Oxaliplatin with and without Paclitaxel Plus Secondary Surgery in Patients with Cisplatin-Refractory and/or Multiply Relapsed Germ Cell Tumors. Eur Urol 60 : 850-855, 2011

71） Oing C, et al : Palliative Treatment of Germ Cell Cancer. Cancer Treat Rev 71 : 102-107, 2018

72） Raggi D, et al : Etoposide, Methotrexate, and Dactinomycin Alternating with Cyclophosphamide and Vincristine （EMACO） for Male Patients with HCG-Expressing, Chemoresistant Germ Cell Tumors. Am J Clin Oncol 40 : 60-65, 2017

73） Oing C, et al : Investigational Targeted Therapies for the Treatment of Testicular Germ Cell Tumors. Expert Opin Investig Drugs 25 : 1033-1043, 2016

74） Chi EA, et al : Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient with Nonseminomatous Germ Cell Tumor. Clin Genitourin Cancer 15 : e855-e857, 2017

75） Zschäbitz S, et al : Activity of Immune Checkpoint Inhibition in Platinum Refractory Germ-Cell Tumors. Ann Oncol 27 : 1356-1360, 2016

76） Zschabitz S, et al : Response to Anti-Programmed Cell Death Protein-1 Antibodies in Men Treated for Platinum Refractory Germ Cell Cancer Relapsed After High-Dose Chemotherapy and Stem Cell Transplantation. Eur J Cancer 76 : 1-7, 2017

77） Adra N, et al : Phase II Trial of Pembrolizumab in Patients with Platinum Refractory Germ Cell Tumors : A Hoosier Cancer Research Network Study GU14-206. Ann Oncol 29 : 209-214, 2018

78） Necchi A, et al : An Open-label Randomized Phase 2 Study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors （APACHE） : Results from the First Planned Interim Analysis. Eur Urol 75 : 201-203, 2019

79） Albany C, et al : Refractory Testicular Germ Cell Tumors Are Highly Sensitive to the Second Generation DNA Methylation Inhibitor Guadecitabine. Oncotarget 8 : 2949-2959, 2017

80） Albany C, et al : A Phase I Study of Guadecitabine （SGI-110） Plus Cisplatin in Patients with Platinum Refractory Germ Cell Tumors. J Clin Oncol 38 : 408, 2020